Background: Hidradenitis suppurativa (HS) is a chronic inflammatory relapsing disease involving the axillae, breast ,groin and anogenital regions. The therapies of the disease are diverse, including medication and surgery. However, responses to treatments are variable and relapse is common, with no single agent being consistently effective.

Objective: To evaluate the efficacy and safety of oral mesalazine treatment for hidradenitis suppurativa .

Methods: Investigators reported a series of cases of patients who received oral mesalazine(1g qid) for hidradenitis suppurativa in our institution between May 2020 and September 2023. A total of 27 patients, 22 in the mild to moderate group and 5 in the severe group, were included in this study.

Inclusion Criteria:

• Recurrent painful or suppurative lesions
• Typical clinical manifestations: the distribution of apocrine sweat glands is deep in painful nodules, abscesses, sinuses, scars;

Exclusion Criteria:

• Severe neurological and psychiatric diseases
• Tumor diseases
• Pregnant women in lactation period

The symptoms of the patients were papules, nodules, cysts, sinuses, pustules, fistulas and scars in the armpits, groin, buttocks, etc., often accompanied by significant pain and tenderness.